Amy Moran, Ph.D., receives a 2021 Young Investigator award from the Prostate Cancer Foundation for her research regarding the role of hormones and immune cells in the most common cancer in men.

The Portland Tribune publishes an article regarding incidents involving research animals at OHSU and Legacy Health; Vickie Jarrell, Ph.D., says: "There's always room for improvement, which is why we do a root cause analysis. Sometimes things do happen that we did not anticipate. When it does happen, we try to prevent it from happening again. Our work does have value and we take it very seriously. We don't use animals unless we absolutely need to for a scientific question."

Three Judith Ann Mogan Foundation gifts totaling $240,000 will support pediatric patients with cancer living on Oregon’s South Coast, as well as students who visit the region through the OHSU Campus for Rural Health.

Two OHSU employees file class action lawsuit against OHSU, citing racial discrimination.

Marcel Curlin, M.D., discusses what to expect from omicron.

Donna Hansel, M.D., Ph.D., tells KGW-TV: "I think we're expecting to see quite a few more [omicron cases]. It sounds like the doubling time of the virus is two to three days and so we expect it may be an exponential increase in the number of positive cases we have."

Two Oregon Health & Science University employees filed a class action lawsuit against the medical center on Tuesday alleging employees of color have been treated unfairly. Gloria Richards and Depreesha Smith claim OHSU “undervalued and over disciplined” minority employees.

Bonnie Nagel, Ph.D., discusses recent research she co-authored showing loneliness is a key predictor in feelings of depression and suicidal ideation. She says online interactions appear not to satisfy core needs for connection: "I don’t think it is genuine human connection when talking to somebody with a fake façade online."

Ahmad Masri, M.D., publishes editorial regarding the implications of a new study that found Metoprolol improves symptoms, quality of life in obstructive hypertrophic cardiomyopathy.

An extremely expensive drug used for multiple sclerosis and other autoimmune disorders provides very little, if any, clinical benefit, according to a new evidence review led by researchers at OHSU and OSU.